Nectin-4 in bladder cancer: biology and predictive biomarker potential
Nectin-4 is a key therapy target in patients with advanced bladder cancer, as demonstrated by the success of enfortumab vedotin. Emerging ADC technologies and Nectin-4-targeted imaging tools could improve efficacy and patient selection, redefining both diagnostic and therapeutic approaches.
Authors
- Navid Roessler (ORCID: https://orcid.org/0009-0008-2792-9828)
- Walter Berger (ORCID: https://orcid.org/0000-0003-0014-1658)
- Bernhard Englinger (ORCID: https://orcid.org/0000-0002-9701-2600)
- Marcin Miszczyk (ORCID: https://orcid.org/0000-0002-4375-0827)
- Markus Eckstein (ORCID: https://orcid.org/0000-0001-5418-3349)
- Shahrokh F. Shariat
Institutions
- Al-Ahliyya Amman University (JO)
- Universität Hamburg (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Cornell University (US)
- Charles University (CZ)
- Universitätsklinikum Erlangen (DE)
- Comprehensive Cancer Center Vienna (AT)
- University Medical Center Hamburg-Eppendorf (DE)
- WSB University (PL)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Current Opinion in Urology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1097/mou.0000000000001354
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00